(HealthDay News) — Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic procedures, ...

Auchincloss said he wants to see Congress “delink” PBMs’ service fees from a drug’s list price and ... animals are at “higher ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded ...

NHS says a quarter of a million people will be offered tirzepatide - brand name Mounjaro - after trials showed it helped obese participants lose a fifth of their body weight ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...